H.R. 3029 · 119th Congress · Science, Technology, Communications
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Amends research law to support nucleic acid screening programs. AI-read
- IntroducedApr 28, 2025 Done
- CommitteeReported Jul 16, 2026 Done
- House floorPassed by voice vote · Jul 20, 2026 Done
- Senate floorIn Senate committee Current stage
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.
Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).
The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)
In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress.
NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.
Congressional Research Service · summary of “Introduced in House” version · Apr 28, 2025
Who lobbies on it
2 organizations · 2 filings · Q2 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Blue Cross Blue Shield of Michigan
1 of 6 quarters
“Issues: Affordable Care Act (ACA), ACA subsidies and tax credits; Telehealth/ telehealth flexibilities; ACA Fraud; Transparency in coverage; Surprise Billing; 2025 Proposed NBPP/Individual Market/ACA exchanges; Rural healthcare; Prior Authorization; Hospital Consolidation; Employer-provided health coverage; Cyber…”
-
Blue Cross and Blue Shield of Kansas Inc
1 of 6 quarters
“Affordable Care Act (ACA), ACA subsidies and tax credits; Telehealth/ telehealth flexibilities; ACA Fraud; Transparency in coverage; Surprise Billing; 2025 Proposed NBPP/Individual Market/ACA exchanges; Rural healthcare; Prior Authorization; Hospital Consolidation; Employer-provided health coverage; Cyber Attack…”
Organizations that named H.R. 3029 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
13 actions · newest first- Jul 21, 2026Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
- Jul 20, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 20, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
- Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
Show all 13 actionsShow fewer
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 3029.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4666-4667)
- Jul 20, 2026Mr. Babin moved to suspend the rules and pass the bill, as amended.
- Jul 16, 2026Placed on the Union Calendar, Calendar No. 654.
- Jul 16, 2026Reported by the Committee on Science, Space, and Technology. H. Rept. 119-751.
- Apr 29, 2025Ordered to be Reported by Voice Vote.
- Apr 29, 2025Committee Consideration and Mark-up Session Held
- Apr 28, 2025Referred to the House Committee on Science, Space, and Technology.
- Apr 28, 2025Introduced in House
What members said about it
-
Ranking Member Lofgren's Opening Statement at Hearing on Biotechnology Innovation and Biosecurity
Today, the House Committee on Science, Space, and Technology is holding an Investigations and Oversight Subcommittee hearing titled, Balancing Biotechnology Innovation and Biosecurity: Securing U.S. Leadership in a Global Race.